B2M and Alzheimer disease: Notably, peripheral B2M clearance via systemic administration of low-dose anti-B2M antibodies effectively reduces brain B2M levels and improves cognitive function in AD mouse models, offering a potential alternative to high-dose Aβ antibody therapies, which frequently induce adverse effects [10].